Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (January 2022)

24 slides from Rockwell Medical's investor presentation, Jan 5, 2022

1. Slide 1: Corporate Presentation January 2022

   Corporate Presentation January 2022 www.RockwellMed.com ROCKWELL MEDICAL, INC. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT (NASDAQ: RMTI)

2. Slide 2: Forward-Looking Statements

   FORWARD - LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical’s intention to develop FPC for new indications, and maintain concentrate sales . Words s

3. Slide 3: Why Rockwell Medical now?

   Why Rockwell Medical now ? 3 Drug platform… ferric pyrophosphate citrate (FPC) Significant growth opportunities… Established dialysis business… 2 nd largest supplier of dialysis concentrates → Home infusion → Dialysis → International partnerships → Future pipeline >$60M sales Biotech opportunity, bu

4. Slide 4: We are investing to drive growth

   4 We are investing to drive growth Commercialized Products in Dialysis » Dialysis Concentrates » Triferic ® » Triferic AVNU ® » Global Expansion Home Infusion Opportunity » FPC for treatment of iron deficiency anemia » Phase II expected to start 1H2022 Development Pipeline » Additional therapies fro

5. Slide 5: Platform Technology: Ferric Pyrophosphate Citrate (FPC)

   PLATFORM TECHNOLOGY Ferric Pyrophosphate Citrate (FPC)

6. Slide 6: Iron Deficiency: What problem needs to be solved?

   6 Iron Deficiency: What problem needs to be s olved ? TRANSFORMING IRON DEFICIENCY AND ANEMIA MANGEMENT » Iron deficiency can develop into a serious medical condition → Often overlooked & undertreated → Hard to treat » Common comorbidity in many diseases especially where there is inflammation → Kidn

7. Slide 7: FPC is a next-generation parenteral iron

   1. Pratt R, et al. Biometals . 2018;31(6):1081 - 1089 2. Fishbane SN, et al. Ferric pyrophosphate citrate (Triferic Ρ ) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015;30(12):2019 - 2026. 7 FPC is a next - generat

8. Slide 8: Home Infusion Opportunity

   HOME INFUSION OPPORTUNITY Newly formulated FPC products Novel presentations 505(b)(1) FDA approvals Unique J - codes Differentiated pricing 8

9. Slide 9: Home infusion is rapidly growing and is an opportunity for FPC

   9 Home infusion is rapidly growing and is an opportunity for FPC . Iron Deficiency Anemia is a common comorbidity . • Large and growing market opportunity • Efficacy and safety already established Presents a significant opportunity for FPC . What is “Home I nfusion” therapy? It is… provision of IV t

10. Slide 10: Management of iron deficiency anemia in home infusion is a broken process

    10 *E.g., stability of parenteral nutrition lipids when delivered with carbohydrate - based IV iron preparations Management of iron deficiency anemia in home infusion patients is a broken process . Traditional IV iron products are not typically used in the home due to concerns with hypersensitivity

11. Slide 11: FPC is uniquely suited to address iron deficiency anemia in home infusion

    11 Bioavailable even in the presence of inflammation and elevated hepcidin. Regular, low doses at home could treat and prevent recurrence of iron deficiency anemia. 3 1. Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate (Triferic Ρ ) administration via the dialysate maintains

12. Slide 12: Home infusion growth driven by multiple trends

    1. NHIA Infusion Industry Trends Report 2020. 12 2010: 829,000 2019: 3,224,427 Home Infusion Therapy Patients Served 1 Home infusion growth driven by multiple trends ▪ Cost and risk of in - person care ▪ New technology ▪ Aging population ▪ COVID - 19 pandemic ▪ Favorable reimbursement TRANSFORMING I

13. Slide 13: Home infusion patient populations are at risk of iron deficiency anemia

    1. NHIA Infusion Industry Trends Report 2020. 2. Hwa YL, Rashtak S, Kelly DG, and Murray JA. Iron deficiency in long - term parenteral nutrition therapy. JPEN 2015. 3. Busti E, et al. Anemia and iron deficiency in cancer patients. Role of iron replacement therapy. Pharmaceuticals 2018, 11, 94. Home

14. Slide 14: Dialysis Opportunities

    ©)ROCKWELL MEDICAL DIALYSIS OPPORTUNITIES

15. Slide 15: Dialysis Concentrates Opportunities for Growth

    15 Dialysis Concentrates Opportunities for Growth We have a strong presence in the hemodialysis market. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANGEMENT

16. Slide 16: Triferic for iron deficiency anemia in hemodialysis

    All hemodialysis patients at risk for iron deficiency anemia Anemia is challenging to manage with the current approach Triferic delivers 100% bioavailable iron, stabilizing hemoglobin 1,2,3 Conveniently delivered via IV * or dialysate 2 Demonstrated to reduce overall cost of anemia drugs 4 16 Full P

17. Slide 17: Triferic market opportunity and success factors

    17 LDO (DaVita) 175k Patients 36% 3 MDOs 58k Patients 10% 490,000 Estimated Total U.S. In - Center Hemodialysis Patients → Current target market is 27% or 132,000 patients Triferic® market opportunity & success factors . TRANSFORMING IRON DEFICIENCY AND ANEMIA MANGEMENT Growth depends on… • Real - w

18. Slide 18: Pipeline Development: Acute Heart Failure

    PIPELINE DEVELOPMENT: ACUTE HEART FAILURE Newly formulated FPC products Novel presentations 505(b)(1) FDA approvals Unique J - codes Differentiated pricing

19. Slide 19: Potential for FPC in treating acute heart failure patients

    Potential for FPC in treating hospitalized acute heart failure patients. □ Why acute heart failure? • > 1 million patients annually • Iron deficiency in 50 - 70% • IV iron improves cardiac energetics in CHF • Iron mobilization limited by inflammation • FPC uniquely suited for acutes - immediately bi

20. Slide 20: Upcoming Milestones

    (©)ROCKWELL MEDICAL UPCOMING MILESTONES

21. Slide 21: Our pipeline

    21 Our pipeline. Product Platforms Target Indications / Products Pre- Clinical U.S. International Triferic® (Dialysate): U.S. Triferic® AVNU (IV): U.S. Triferic® : Canada Triferic® : Korea Triferic® : India Triferic® : China Iron Deficiency Anemia in the Home Infusion Setting FPC Rock-201: U.S. Phas

22. Slide 22: Management Team

    Proven track record and expertise in biopharmaceutical commercialization and clinical development 22 Management Team Marc Hoffman, M.D. Chief Medical Officer Years: 30+ Our experienced management team. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANGEMENT Mike DeYoung VP Operations Years: 25 + Russell E

23. Slide 23: Commercial stage biopharmaceutical company investing in growth

    Rockwell Medical is a commercial stage biopharmaceutical company investing in growth 23 x Proprietary Platform Technology Applicable To Many Disease States x Significant Growth Opportunities in new indications » Home Infusion » Pipeline: Acute Heart Failure x Building on the Success of a Significant

24. Slide 24: Thank You

    ROCKWELL MEDICAL THANKYOU

Rockwell Medical — Investor Presentation (January 2022) on 6ix